AuraVax Therapeutics awarded contract from BARDA to evaluate NanoSTING platform as mucosal adjuvant for intranasal pandemic influenza vaccine
AuraVax Therapeutics awarded contract from BARDA to evaluate NanoSTING platform as mucosal adjuvant for intranasal pandemic influenza vaccine
10/29/24, 12:19 PM
Location
houstonIndustry
therapeutics
biotechnology
health care
Type
contract
AuraVax Therapeutics, Inc. has been awarded a preclinical research contract from the Biomedical Advanced Research and Development Authority (BARDA) to evaluate NanoSTING-002 as a mucosal adjuvant for intranasal pandemic influenza vaccine. The contract aims to demonstrate the efficacy of NanoSTING-002 with intranasal live-attenuated vaccines to improve immune protection and provide a path to a universal vaccine.
Company Info
Location
houston, texas, united states
Additional Info
AuraVax Therapeutics, Inc. (AuraVax) is a privately held biotechnology company commercializing a new platform termed "NanoSTING" to activate STING for the treatment and prevention of respiratory infections independent of the infecting virus. NanoSTING is a broad-acting, host-directed intranasal immune-antiviral to safely target the STING pathway and restore innate immunity for the prevention and treatment of respiratory disease as well as disrupt host-to-host transmission.
For more information about AuraVax, please visit: https://www.auravax.com/
For additional information about AuraVax, contact Joseph Sullivan at jsullivan@auravax.com; 267-421-9792.
SOURCE AuraVax Therapeutics